Literature DB >> 19240158

Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population.

Monica Mortensen1, David A Ehrmann, Elizabeth Littlejohn, Robert L Rosenfield.   

Abstract

CONTEXT/
OBJECTIVE: Our objective was to determine the ovarian function of asymptomatic volunteers with a polycystic ovary (V-PCO). PARTICIPANTS: Non-hirsute eumenorrheic V-PCO (n = 32) and volunteers with ultrasonographically normal ovaries (V-NO) (n = 21) were compared with one another and with polycystic ovary syndrome (PCOS) patients who met National Institute of Health criteria (n = 90). DESIGN/SETTING/
INTERVENTIONS: GnRH agonist (GnRHag), ACTH, and oral glucose tolerance tests were prospectively performed in a General Clinical Research Center.
RESULTS: The distribution of 17-hydroxyprogesterone (17OHP) responses to GnRHag of V-PCO formed a distinct population intermediate between that of V-NO, the reference population, and PCOS. Nevertheless, the V-PCO population was heterogeneous. There were 53% (seventeen of 32) that were functionally normal, with 17OHP responses and free testosterone levels like V-NO. A total of 25% (eight of 32) had an elevated free testosterone, thus meeting Rotterdam criteria for PCOS; one third of these had 17OHP hyperresponsiveness to GnRHag testing. The remaining 22% (seven of 32) had 17OHP hyperresponsiveness to GnRHag, but normal free testosterone. Of PCOS, 69% had elevated 17OHP hyperresponsiveness to GnRHag. Ovarian volume correlated significantly with 17OHP responses only in PCOS, accounting for just 10% of the variance.
CONCLUSIONS: Many asymptomatic volunteers have a PCO. They are a distinct, but heterogeneous, population with respect to ovarian function, ranging from normal (53%) to occult PCOS by Rotterdam criteria (25%). Nearly one quarter (22%) had the typical PCOS type of ovarian dysfunction without hyperandrogenemia, termed a "dysregulated PCO"; they or their offspring may be at risk for PCOS. Ovarian ultrasonographic characteristics must be considered when establishing norms for ovarian function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19240158      PMCID: PMC2684482          DOI: 10.1210/jc.2008-2771

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

1.  Testosterone binding and free plasma androgen concentrations under physiological conditons: chararacterization by flow dialysis technique.

Authors:  G W Moll; R L Rosenfield
Journal:  J Clin Endocrinol Metab       Date:  1979-11       Impact factor: 5.958

2.  Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin.

Authors:  M H van Hooff; F J Voorhorst; M B Kaptein; R A Hirasing; C Koppenaal; J Schoemaker
Journal:  Fertil Steril       Date:  2000-07       Impact factor: 7.329

3.  Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.

Authors:  P L Chang; S R Lindheim; C Lowre; M Ferin; F Gonzalez; L Berglund; E Carmina; M V Sauer; R A Lobo
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

4.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

5.  Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone.

Authors:  J Adams; S Franks; D W Polson; H D Mason; N Abdulwahid; M Tucker; D V Morris; J Price; H S Jacobs
Journal:  Lancet       Date:  1985 Dec 21-28       Impact factor: 79.321

6.  Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.

Authors:  Judith M Adams; Ann E Taylor; William F Crowley; Janet E Hall
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

7.  How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?

Authors:  R N Clayton; V Ogden; J Hodgkinson; L Worswick; D A Rodin; S Dyer; T W Meade
Journal:  Clin Endocrinol (Oxf)       Date:  1992-08       Impact factor: 3.478

Review 8.  Ultrasound assessment of the polycystic ovary: international consensus definitions.

Authors:  Adam H Balen; Joop S E Laven; Seang-Lin Tan; Didier Dewailly
Journal:  Hum Reprod Update       Date:  2003 Nov-Dec       Impact factor: 15.610

9.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

Authors: 
Journal:  Fertil Steril       Date:  2004-01       Impact factor: 7.329

10.  Polycystic ovaries--a common finding in normal women.

Authors:  D W Polson; J Adams; J Wadsworth; S Franks
Journal:  Lancet       Date:  1988-04-16       Impact factor: 79.321

View more
  23 in total

1.  Interventional studies for polycystic ovarian syndrome in children and adolescents.

Authors:  Patricia Myriam Vuguin
Journal:  Ped Health       Date:  2010-02

Review 2.  The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum.

Authors:  Robert L Rosenfield
Journal:  J Pediatr Adolesc Gynecol       Date:  2014-08-27       Impact factor: 1.814

3.  Mutations of the hexose-6-phosphate dehydrogenase gene rarely cause hyperandrogenemic polycystic ovary syndrome.

Authors:  Kenan Qin; Robert L Rosenfield
Journal:  Steroids       Date:  2010-11-02       Impact factor: 2.668

Review 4.  Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity.

Authors:  Robert L Rosenfield; Brian Bordini
Journal:  Brain Res       Date:  2010-09-25       Impact factor: 3.252

5.  Evidence for gonadotrophin secretory and steroidogenic abnormalities in brothers of women with polycystic ovary syndrome.

Authors:  D M Liu; L C Torchen; Y Sung; R Paparodis; R S Legro; S K Grebe; R J Singh; R L Taylor; A Dunaif
Journal:  Hum Reprod       Date:  2014-10-21       Impact factor: 6.918

Review 6.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 7.  Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.

Authors:  Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

Review 8.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

Review 9.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

10.  Relationship between 17-hydroxyprogesterone responses to human chorionic gonadotropin and markers of ovarian follicle morphology in women with polycystic ovary syndrome.

Authors:  Kevin H Maas; Sandy S Chuan; Heidi Cook-Andersen; H Irene Su; A Duleba; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.